Is GHRP-6 FDA-approved, and what does the research show?

What is GHRP-6?

GHRP-6, growth hormone-releasing peptide-6, is a synthetic hexapeptide, a chain of six amino acids made in a laboratory ². It belongs to the growth hormone-releasing peptides, a family of "potent growth hormone secretagogues," substances that make the pituitary gland release its own growth hormone ¹. The family acts through the ghrelin receptor, the receptor for ghrelin, a hormone produced by the stomach ¹, ¹¹. Hexarelin and GHRP-2 are related peptides of the same family ¹, ¹².

Is GHRP-6 FDA-approved?

GHRP-6 is not FDA-approved: Drugs@FDA lists no approved GHRP-6 product as of November 9, 2026 ³. Its published human studies include hormone tests in healthy men, a single-dose diagnostic study and two randomized stroke trials of a combination with epidermal growth factor ², ⁶, ⁸, ⁹.

FDA has placed GHRP-6 on both of its lists of substances nominated for compounding. On the 503A list, which covers licensed pharmacies, GHRP-6 sits in Category 3, under FDA's heading "Bulk Drug Substances Nominated Without Adequate Support"; the list is dated May 14, 2026 ⁴.

On the 503B list, which covers outsourcing facilities, compounders "registered under section 503B" of the federal drug law ¹³, GHRP-6 sits in Category 2 ⁵. FDA's heading there reads "Bulk Drug Substances that Raise Significant Safety Risks," and that list is dated March 21, 2025 ⁵. FDA's safety page dates the Category 2 entry September 29, 2023 ¹⁴.

FDA's January 2025 interim policy on 503A compounding says of Category 3: "These substances may be eligible for inclusion on the 503A bulks list but were nominated with insufficient supporting information for FDA to evaluate them" ¹⁵. Its 503B policy says of Category 2 that FDA "has identified significant safety risks relating to the use of these substances in compounding pending further evaluation and, therefore, does not intend to adopt the policy described for the substances in Category 1" ¹³. None of the FDA documents opened for this page describes a route by which a licensed pharmacy may compound GHRP-6.

See the FDA status of every peptide, updated weekly.

How does GHRP-6 work?

GHRP-6 binds the ghrelin receptor, found mainly in the hypothalamus and pituitary ¹, ¹¹. Studied in people, nine healthy young men given a 34-hour intravenous infusion, GHRP-6 made growth hormone pulses larger without changing their number ². Blood insulin-like growth factor-I, or IGF-I, rose during the infusion, and the pituitary stayed responsive throughout ². The authors call the mechanism "uncertain" and discuss whether GHRP-6 blocks somatostatin, the hormone that holds growth hormone back ².

In healthy men it also raised cortisol, the adrenal stress hormone, and ACTH, the pituitary hormone that drives cortisol ⁷. That is the opposite of GHRH, the body's own growth hormone-releasing hormone, which, given in pulses, blunts cortisol ⁷.

The ghrelin receptor is also present in heart and blood-vessel tissue ¹¹. A 2006 review proposes protective and vessel effects for the family, with the signaling "not documented fully" ¹¹.

What does the research show?

Studied in people: a multicenter study of 125 adults with pituitary disease and severe growth hormone deficiency, and 125 healthy adults ⁶. Each was given one intravenous dose of GHRP-6 with GHRH as a diagnostic test ⁶. The combined test separated the two groups more sharply than the insulin tolerance test, the standard test ⁶. The authors proposed it as "a convenient, safe and reliable test" for adult growth hormone deficiency ⁶. This is GHRP-6 as a single-dose diagnostic agent, not as a treatment.

Studied in people: a randomized, open-label phase 3 trial of 188 patients with acute ischemic stroke, enrolled within 12 hours of onset ⁸. Ninety-five received intravenous epidermal growth factor plus GHRP-6 twice daily for seven days, and 93 received standard care alone ⁸. In the whole trial, disability scores at three and six months, daily-living scores and survival did not differ between the groups ⁸. The authors say the study "missed the primary endpoint" ⁸.

In a subgroup of 27 patients with severe stroke, those treated had less disability at six months and a lower mortality risk ⁸. The authors offer this as a reason for further study ⁸. The trial came from Cuba's Center for Genetic Engineering and Biotechnology, which employs several of the authors, and it tested GHRP-6 only in combination ⁸.

An earlier phase 1/2 trial by the same group randomized 36 stroke patients to the combination at two strengths or to standard care ⁹. Safety over six months was the primary endpoint ⁹. The authors concluded the combination "was safe" and reported better neurological and functional scores in the treated groups ⁹. Neither trial had an arm given GHRP-6 alone ⁸, ⁹.

Studied in people: two further placebo-controlled studies in healthy men by one research group ⁷, ¹⁰. Four intravenous boluses overnight increased stage 2 sleep but left deep, slow-wave sleep unchanged, while raising ACTH and cortisol ⁷. Given by mouth in enteric-coated capsules, GHRP-6 left growth hormone, ACTH and cortisol unchanged; given into the nose it raised growth hormone through the night ¹⁰. No published trial of GHRP-6 for muscle, bone, body composition or healing was found in PubMed's clinical-trial records or on ClinicalTrials.gov on November 9, 2026.

What are the side effects?

FDA has written its own safety words on GHRP-6, on its page about bulk substances that may present significant safety risks, current as of April 22, 2026 ¹⁴. Compounded drugs containing GHRP-6 "may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities" ¹⁴. FDA adds that it "has identified limited safety-related information, but the available data reveal safety concerns including potential effect on cortisol and increase in blood glucose due to decreases in insulin sensitivity" ¹⁴.

The human studies match the cortisol concern. In healthy men, GHRP-6 raised ACTH and cortisol overnight against placebo ⁷. During the 34-hour infusion, baseline thyroid-stimulating hormone was lower than during saline, and the pituitary's responses to two test hormones were smaller ². The single-dose diagnostic test in 250 people "did not result in any side-effects" ⁶.

In the stroke trial, severe adverse events occurred in 48 of 188 patients, 30 of the 95 treated and 18 of the 93 on standard care ⁸. The authors judged none of them treatment-related ⁸. In the earlier phase 1/2 trial, serious adverse events occurred in 9 of 16 patients on standard care ⁹. They occurred in 3 of 10 and 2 of 10 in the two treated groups, and two events in one treated patient were attributed to the treatment ⁹. No study opened for this page gave GHRP-6 for longer than seven days ⁸, ⁹.

In sport

WADA, the World Anti-Doping Agency, names GHRP-6 on its 2026 Prohibited List under S2.2.4, "Growth hormone releasing factors," in the line "GH-releasing peptides (GHRPs) [e.g. alexamorelin, examorelin (hexarelin), GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5 and GHRP-6]" ¹². Class S2, peptide hormones, growth factors, related substances and mimetics, is prohibited at all times, in and out of competition ¹². The list's M2.2 also prohibits "intravenous infusions and/or injections of more than a total of 100 mL per 12-hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations" ¹².

What JumpstartMD offers

JumpstartMD does not prescribe GHRP-6. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 9, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.